Frequency of deep vein thrombosis among hospitalized non-surgical Japanese patients with congestive heart failure

Matsuo, Hiroshi; Matsumura, Makoto; Nakajima, Yoshie; Ogawa, Tomohiro; Tazaki, Junichi; Doi, Takahiro; Yamada, Norikazu; Koide, Takao; Mo, Makoto; Suzuki, Takeo; Sarai, Nobuaki; Nakajima, Hitoshi

doi:10.1016/j.jjcc.2014.02.028

Cited by 15 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…132,[137][138][139][140] Experimental data support this proposition to some degree, 141 and evidence in humans suggests that antiplatelet drugs do decrease the risk of venous thrombosis. [142][143][144][145] However, this should be viewed in the context of the substantial body of evidence in humans supporting administration of anticoagulants as first line prophylactic drugs for venous thrombosis. 146…”

Section: Strength Of Recommendation: Weakmentioning

confidence: 99%

ACVIM consensus statement on the treatment of immune‐mediated hemolytic anemia in dogs

Swann

Garden

Fellman

et al. 2019

Veterinary Internal Medicne

187

View full text Add to dashboard Cite

Immune‐mediated hemolytic anemia (IMHA) causes severe anemia in dogs and is associated with considerable morbidity and mortality. Treatment with various immunosuppressive and antithrombotic drugs has been described anecdotally and in previous studies, but little consensus exists among veterinarians as to the optimal regimen to employ and maintain after diagnosis of the disease. To address this inconsistency and provide evidence‐based guidelines for treatment of IMHA in dogs, we identified and extracted data from studies published in the veterinary literature. We developed a novel tool for evaluation of evidence quality, using it to assess study design, diagnostic criteria, explanation of treatment regimens, and validity of statistical methods. In combination with our clinical experience and comparable guidelines for humans afflicted with autoimmune hemolytic anemia, we used the conclusions of this process to make a set of clinical recommendations regarding treatment of IMHA in dogs, which we refined subsequently by conducting several iterations of Delphi review. Additionally, we considered emerging treatments for IMHA in dogs and highlighted areas deserving of future research. Comments were solicited from several professional bodies to maximize clinical applicability before the recommendations were submitted for publication. The resulting document is intended to provide clinical guidelines for management of IMHA in dogs. These guidelines should be implemented pragmatically, with consideration of animal, owner, and veterinary factors that may vary among cases.

show abstract

Section: Strength Of Recommendation: Weakmentioning

confidence: 99%

ACVIM consensus statement on the treatment of immune‐mediated hemolytic anemia in dogs

Swann

Garden

Fellman

et al. 2019

Veterinary Internal Medicne

187

View full text Add to dashboard Cite

show abstract

“…A prospective, international, multicenter, observational study of a cohort of consecutive Asian patients indicates that congestive heart failure is a risk factor for venous thromboembolic events, whose odds ratio is within the range of Western patients [6]. Some recent studies found that reduced cardiac function is an independent risk factor for VTE in Asians as well as in Caucasians [6, 23–25]. …”

Section: Risk Factor and Incidencementioning

confidence: 99%

Reduced cardiac function and risk of venous thromboembolism in Asian countries

Zhu

Tang

2017

Thrombosis J

View full text Add to dashboard Cite

Patients with reduced cardiac function are thought to have a higher risk of venous thromboembolism (VTE). Additionally, they are vulnerable to complications of pulmonary embolism (PE) as well as right heart failure (HF), which in return is supposed to increase the rate of mortality. Studies focusing on VTE in heart failure patients were rare in Asian countries before the 21st century. Nowadays, more and more data are becoming available in this field in Asia. It is already known that heart failure can increase the risk of VTE, but so far a consensus on this issue has not been reached for many years, not only in Asian countries but all over the world. This condition may be due to the detailed pathological advancement in Virchow’s triad and some other theories. In clinical practice, VTE, especially PE is difficult to diagnose in patients with heart failure because of overlapping symptoms (e.g. cough and chest pain) and the elevation of laboratory markers (e.g. probrain natriuretic peptide (NT-proBNP) and D-dimer in both heart failure and VTE patients). Management of VTE in heart failure patients is also controversial because heart failure patients always have complications, such as renal failure and hepatic failure, which increase the risk of bleeding. In this study, we analyzed data from China, Japan, Korea, Singapore and India mainly to get a better understanding of the research progress in VTE in patients with heart failure. The aim of this review is to discuss the risk, incidence, advancement of diagnosis, management and prevention of VTE in patients with heart failure in Asian countries.

show abstract

“…The incidence of venous thromboembolism (VTE) has been increasing for decades because of the aging population, obesity, Western dietary habits, advances in the diagnostic skills, increasing social awareness, and heart failure [1,2]. A standard anticoagulant therapy, the initial use of unfractionated heparin (UFH) with a transition to warfarin, has been developed and broadly utilized in treating acute VTE [1].…”

Section: Introductionmentioning

confidence: 99%

A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism

Kabuki

Nakanishi

Hisatake

et al. 2017

Journal of Cardiology

View full text Add to dashboard Cite

show abstract

Frequency of deep vein thrombosis among hospitalized non-surgical Japanese patients with congestive heart failure

Cited by 15 publications

References 17 publications

ACVIM consensus statement on the treatment of immune‐mediated hemolytic anemia in dogs

ACVIM consensus statement on the treatment of immune‐mediated hemolytic anemia in dogs

Reduced cardiac function and risk of venous thromboembolism in Asian countries

A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism

Contact Info

Product

Resources

About